Incyte/Merck's ECHO-301 Failure Casts More Shadow On IDO Space

 
• By Emily Hayes

Following failure of Incyte/Merck's epacadostat/Keytruda study, NewLink Genetics says it is reviewing its IDO clinical programs.

Desperate businessmen

More from Immuno-oncology

More from Anticancer